Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Rosemary Mazanet, MD
NKT Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Children'S Hospital & Research Center at Oakland
Oakland, California, United States
- Johns Hopkins School of Medicine
Baltimore, Maryland, United States
- Brigham and Women'S Hospital
Boston, Massachusetts, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Unc Sickle Cell Program
Chapel Hill, North Carolina, United States
- Blood Center of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2013
- Primary completion
- 31 May 2015
- Completion
- 31 May 2015
- Last update posted
- 26 Jun 2015
- Registered enrollment
- 21
- Registry id
- NCT01783691
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.